THE FIBROUS CAP: A PROMISING TARGET IN THE PHARMACOTHERAPY OF ATHEROSCLEROSIS

Stanislav Yanev¹, Maria D. Zhelyazkova-Savova², and George N. Chaldakov³, ⁴*

¹Institute of Neurobiology, Department of Drug Toxicology, Bulgarian Academy of Sciences, Sofia, Bulgaria,
²Department of Pharmacology and Clinical Pharmacology and Therapeutics, Medical University, Varna, Bulgaria,
³Department of Anatomy and Cell Biology, Medical University, Varna, Bulgaria, and
⁴Institute for Advanced Study, Varna, Bulgaria

Recent advances have shed light on the relationship between smooth muscle cell (SMC) phenotypic modulation, resolution of inflammation and atherosclerotic plaque stability. The thick fibrous cap covering the lipid core of plaques is composed of bundles of SMC and collagen fibers and few macrophages and lymphocytes, all of which make the plaque resistant to rupture. The thin fibrous cap contains many macrophages and lymphocytes, few SMC and less collagen fibers, all of which may weaken the cap, leaving the plaque vulnerable to rupture. In the present Dance Round, we, at a pharmacotherapeutic level, address the possibility of how the control over the activity of the essential cellular components of the plaque, particularly its fibrous cap, could be implicated in plaque stabilization, focusing on (i) the modulation of SMC from contractile to secretory (fibrogenic) phenotype, (ii) the control on plaque inflammation-resolution processes, and (iii) the reduction of plaque lipid content. Further studies on both unstable plaque and aortic aneurysm, which share a similar, matrix-based vulnerability, may bring new insights for pharmacotherapy of vascular injuries. Biomed Rev 2019; 30:136-141

Keywords: atherosclerotic plaque, fibrous cap, smooth muscle cells, collagen, phenotypic modulation, macrophages, matrix metalloproteinases, pro-resolving mediators, acetylcholine, nerve growth factor
The new paradigm should be not only different but also better.

Thomas S. Kuhn, The Structure of Scientific Revolutions, 1932

In 2017 Dance Round one of us together with his colleagues (1) described the following chronology in the ideogenesis of atherosclerosis:

(i) during the 1960’s the great lady of atherosclerosis research Maria Daria Haust proposed the first paradigm shift in the field pointing to a new, synthetic versus contractile function of the artery smooth muscle cells (SMC);

(ii) in the 1970’s, we published the first transmission electron microscopic data of this new function conceptualizing it as “secretory function” instead of “synthetic function” of SMC as has been previously considered (reviewed in (2, 3);

(iii) in the 1980’s, atherosclerosis was rediscovered as an inflammatory disease (4);

(iv) in the 1990’s and 2000’s, the next paradigm shift has emerged, namely from the inhibition of SMC proliferation (4) and secretion (5, 6) to the stimulation of these same processes aimed at the plaque stabilization by increasing fibrous cap thickness. Briefly, the increased secretion of matrix molecules, particularly (pro)collagen, by SMC could “shift” them from enemies to friends in the fight against the unstable atherosclerotic plaque (1, 7-9).

Yet, it is not clear why fibrous cap destruction takes place in macrophage-rich shoulder regions of the atherosclerotic plaque. Impaired cap formation caused by SMC senescence and/or proneness to apoptosis may also be critical in promoting plaque rupture.

In the present Dance Round, we, at a pharmacotherapeutic level, focus on the fibrous cap stabilization targeting (i) the stimulation of SMC secretory (fibrogenic) and proliferative activity, (ii) the inhibition of rupturogenic potential of macrophages and lymphocytes, and (iii) the reduction of atheroma (plaque lipid core). The plaque regression, resulting in the overall reduction in plaque volume (10, 11), is out of scope of the present Dance Round.

Of note, keeping in mind the importance of fibrous cap for the vulnerability of the plaque, we must proceed cautiously with the colchicine administration for cardiovascular diseases (5, 12 and references therein), which antifibrotic action could decrease the thickness of fibrous cap making it vulnerable to erosion and/or rupture.

Atherosclerosis is a low-grate inflammatory disease characterized by occlusion of large- and medium-sized arteries due to the formation of plaques (4). Plaque instability has been associated with erosion, ulceration or rupture of the fibrous cap that covers plaque lipid core. Recent advances have shed light on the relationship between SMC phenotypic modulation, inflammation-resolution and plaque vulnerability-stability (14-17).

**Fibrous Cap Composition**

The thick fibrous cap covering the lipid core of atherosclerotic plaques is composed of bundles of SMC (and myofibroblasts?) and collagen fibers and few macrophages and lymphocytes. The thin fibrous cap contains many macrophages and lymphocytes, few SMC and less collagen fibers, all of which may weaken the cap, leaving the plaque vulnerable to rupture. This tends to occur in areas where the cap is the thinnest and most heavily infiltrated by macrophages. These are plaque shoulder region defined as the junction between the plaque and the adjacent, less diseased artery wall (Table 1, Fig. 1). In advanced atherosclerotic lesions calcification of the fibrous cap can develop.

**Table 1. Major features of unstable atherosclerotic plaque**

| **Thin fibrous cap (< 100 micrometer)** |
|-----------------------------------------|
| Increased presence of macrophages and lymphocytes |
| Low presence of SMC and collagen fibers |
| Large lipid core (> 30% of the total volume of plaque) |
| Presence of intraplaque hemorrhage |
| Cap erosion and thrombus formation |
| Increased expression of matrix degrading MMP |
| Reduced expression of tissue inhibitors of MMP (TIMP) |

*SMC, smooth muscle cells; MMP, Matrix metalloproteinases
TIMP: Tissue inhibitors of metalloproteinases

To recap, the paradigm was shifted from the plaque size to the plaque stability, that is, the thickness of fibrous cap - the thicker the cap, the more stable the plaque. Accordingly, plaque stabilization has appeared as a promising therapeutic approach for the therapy of atherosclerosis (Fig. 2).
Fibrous cap - targeted pharmacotherapy

Molecular aspects of this phenomenon as related to plaque stability are not fully defined. Recently, it was demonstrated that a signaling cross-talk between fibroblast growth factor (FGF) and transforming growth factor-beta (TGF-β) in SMC plays an important role in the atherogenesis, namely, the inhibition of FGF signaling increases TGF-β activity, resulting in a significant increase of fibrous cap thickness and decrease of lipid core size (18).

Likewise, the critical role of SMC phenotypic modulation in aortic aneurysm and dissection in Marfan syndrome is intensively studied (19-23). Note, both unstable (thin) fibrous cap and aortic aneurysm share a similar, matrix-based vulnerability.

Metalloproteinases inhibitors
Since metalloproteinases (MMP) favor matrix (collagen, elastin, and proteoglycans) degradation, the decrease of MMP activity may have a stabilizing action on the fibrous cap (24-27): In this vein, doxycycline, a MMP-2 and MMP-9 inhibitor, significantly delays thoracic aorta aneurysm rupture in Marfan syndrome-like mice (19, 20). Because of the safety profile of the tetracyclines, clinical trials should be organized to determine if doxycycline could also delay the progression of plaque instability. Another MMP-related example is the phosphinic peptide (RXP470.1) which is a selective murine MMP-12 inhibitor (28).

Specialized pro-resolving mediators
Defective resolution of inflammation is the underlying cause of various chronic inflammatory diseases, including atherosclerosis and other cardiometabolic diseases. Inflammation-resolution are active processes aimed at restoration of tissue integrity and function. These are governed in part by endogenously synthesized pro-resolving mediators, such as lipoxins, resolvins, protectins, and maresins. Compromised inflammation-resolution is an important driving force in the progression of atherosclerosis and, respectively, a promising pharmacological target for its therapy (29). In effect, the “resolution pharmacology” might be a therapeutic option for atherosclerosis (30).

Omega-3 essential fatty acids serve as substrates for the formation of a group of lipid-derived mediators that participate in the resolution of inflammation. Among them, the eicosapentaenoic acid (EPA)-derived resolvin E1 appears to be of particular interest, as dietary supplemented EPA was found to preferentially be distributed in thin fibrous cap, implying an important plaque stabilizing potential (31).

FACTORS INVOLVED IN PLAQUE STABILIZATION
Possible ways for the stabilization of fibrous cap might be: (i) making the cap more fibrous, (ii) attenuating inflammation, stimulating the resolution of inflammation, and (iii) reducing plaque lipid content.

Phenotypic modulation of SMC
Traditionally, the conversion from contractile to secretory phenotype of SMC was thought to play a pivotal role in the pathobiology of atherosclerosis (1, 4-6). However, the molecular aspects of this phenomenon as related to plaque stability are not fully defined. Recently, it was demonstrated that a signaling cross-talk between fibroblast growth factor (FGF) and transforming growth factor-beta (TGF-β) in SMC plays an important role in the atherogenesis, namely, the inhibition of FGF signaling increases TGF-β activity, resulting in a significant increase of fibrous cap thickness and decrease of lipid core size (18).

Likewise, the critical role of SMC phenotypic modulation in aortic aneurysm and dissection in Marfan syndrome is intensively studied (19-23). Note, both unstable (thin) fibrous cap and aortic aneurysm share a similar, matrix-based vulnerability.

Metalloproteinases inhibitors
Since metalloproteinases (MMP) favor matrix (collagen, elastin, and proteoglycans) degradation, the decrease of MMP activity may have a stabilizing action on the fibrous cap (24-27): In this vein, doxycycline, a MMP-2 and MMP-9 inhibitor, significantly delays thoracic aorta aneurysm rupture in Marfan syndrome-like mice (19, 20). Because of the safety profile of the tetracyclines, clinical trials should be organized to determine if doxycycline could also delay the progression of plaque instability. Another MMP-related example is the phosphinic peptide (RXP470.1) which is a selective murine MMP-12 inhibitor (28).

Specialized pro-resolving mediators
Defective resolution of inflammation is the underlying cause of various chronic inflammatory diseases, including atherosclerosis and other cardiometabolic diseases. Inflammation-resolution are active processes aimed at restoration of tissue integrity and function. These are governed in part by endogenously synthesized pro-resolving mediators, such as lipoxins, resolvins, protectins, and maresins. Compromised inflammation-resolution is an important driving force in the progression of atherosclerosis and, respectively, a promising pharmacological target for its therapy (29). In effect, the “resolution pharmacology” might be a therapeutic option for atherosclerosis (30).

Omega-3 essential fatty acids serve as substrates for the formation of a group of lipid-derived mediators that participate in the resolution of inflammation. Among them, the eicosapentaenoic acid (EPA)-derived resolvin E1 appears to be of particular interest, as dietary supplemented EPA was found to preferentially be distributed in thin fibrous cap, implying an important plaque stabilizing potential (31). The direct re-
petitive delivery of pro-resolving mediators themselves also suggests a potentially innovative strategy for resolving arterial inflammation. The systemic administration of resolvins D2 and maresin 1 has been shown in a mice model of athero-progression to prevent the expansion of the necrotic core and the accumulation of macrophages, simultaneously increasing the number of SMC and the fibrous cap thickness (32).

**Acetylcholine anti-inflammatory pathway**

The cholinergic anti-inflammatory pathway is dependent on the nicotinic acetylcholine receptor α7 subunit. Accordingly, selective acetylcholine receptor α7 agonists reduce the level of pro-inflammatory mediators (e.g. TNF-alpha) in experimental models of inflammatory disease (33). Notably, as reported by Rosso et al in this volume of Biomedical Reviews, vagus nerve stimulation leads to the increased expression of nerve growth factor (NGF), the latter being also a subject of discussion in the present Dance Round (see next section and Table 2).

Further studies on the cholinergic anti-inflammatory mechanisms may provide new insights for the pathogenesis and therapy of atherosclerosis.

**Nerve growth factor**

In addition to platelet-derived growth factor, FGF and other fibrogenic factors (for galectin-3 see Kisheva and Yotov in this volume of Biomedical Reviews), recent studies have demonstrated that nerve growth factor (NGF) has effects on myofibroblasts and collagen synthesis, and, respectively, fibrotic disorders (34, 35).

Keeping in mind that (i) atherosclerotic plaque may be viewed as a vascular wound (1, 4), (ii) topical application of NGF expresses healing effects on corneal ulcers, diabetic wounds, pressure ulcers, and chronic vasculitic ulcers (36-38), and (iii) reduced local and circulating level of NGF was found in human coronary atherosclerosis and metabolic syndrome (39), we suggest that NGF may also demonstrate healing effect on atherosclerotic plaque (vascular wound).

Noteworthy, Professor Russell Ross (1929-1999), the author of more than 300 peer-reviewed papers including the seminal review cited herein (4), has started his research career on cell biology of skin wound before became one of the most renowned scientists in the field of atherosclerosis.

A summing-up list of agents with potentials for plaque stabilization is shown in Table 2.

---

**Table 2. Selected list of possible plaque stabilizers**

| Category | Agents |
|----------|--------|
| Stabilizers of matrix molecule secretion by smooth muscle cells (SMC)* | • Stimulators of matrix molecule secretion by smooth muscle cells (SMC)* |
| Matrix metalloproteinases-targeting agents | • Matrix metalloproteinases-targeting agents |
| • Inhibitors of matrix metalloproteinases | o Inhibitors of matrix metalloproteinases |
| • Activators of tissue inhibitor of metalloproteinases | o Activators of tissue inhibitor of metalloproteinases |
| Inflammation-targeting agents | • Inflammation-targeting agents |
| • Inhibitors of inflammation | o Inhibitors of inflammation |
| • Stimulators of resolution of inflammation | o Stimulators of resolution of inflammation |
| Acetylcholine-targeting agents | • Acetylcholine-targeting agents |
| • Nicotinic acetylcholine receptor α7 agonists | o Nicotinic acetylcholine receptor α7 agonists |
| Lipid-targeting agents | • Lipid-targeting agents |
| o Inhibitors of phosphatidylcholine phospholipase C (40) | – The xanthate selective inhibitor D609 (41); new selective inhibitors (chiral derivatives of tetrahydrobenzo-oxazepines) (42) |
| o Inhibitors of sphingomyelin synthase 2 | – D609 (43); Ly93 (2-benzyloxybenzamides analog) (44) |
| o Statins (10) | o PCSK-9 (pro-protein convertase subtilisin/kexin type 9) inhibitors: evolocumab, alirocumab (45, 46) |
| o PCSK-9 (pro-protein convertase subtilisin/kexin type 9) inhibitors: evolocumab, alirocumab (45, 46) | • NGF and TrkANGF receptor agonists (3) |

* For SMC apoptosis and proliferation, also lipids, see Fig. 2. For decrease of macrophage proliferation, see (47).

---

**EPILOGUE**

Rapidly accelerating knowledge and continued research promise to provide further progress in the prevention and therapy of cardiovascular disease. Atherosclerotic plaque is like a volcano that sleeps - if it erupts, its lava stops the blood flow and the oxygen-deprived heart becomes numb - the silence of the heart is called myocardial infarction.

- Vulnerable plaque
- Vulnerable blood
- Vulnerable myocardium
- Vulnerable patient
- Vulnerable society

**CONFLICT OF INTEREST**

The authors have no conflict of interest to disclose.

**ACKNOWLEDGEMENTS**

We thank Nikifor N. Chaldakov for the colored atherosclerotic plaques presented in Figure 1.
REFERENCES

1. Ghenev PI, Aloe L, Kisheva AR, Singh M, Panayotov P, Fiore M, et al. QUO VADIS, ATEROGENESIS? Part 1. Smooth muscle cell secretion – how foe becomes friend in the fight against the atherosclerotic plaque. Biomed Rev 2017; 28:134-138.

2. Chaldakov GN. George E. Palade lecture. Human body as a multicircine system, with special reference to cell protein secretion: From vascular smooth muscles to adipose tissue. Biomed Rev 2016; 27(VIII - XIX).

3. Yanev S, Fiore M, Hinev A, Ghenev PI, Hristova MG, Panayotov P, et al. From antitubulins to trackins. Biomed Rev 2016; 27:59-67.

4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340(2): 115-126. [DOI: 10.1056/NEJM199901143400207]

5. Chaldakov GN. Antitubulins - a new therapeutic approach for atherosclerosis? Atherosclerosis 1982; 44(3): 385-390. [DOI: 10.1016/0021-9150(82)90137-1]

6. Chaldakov GN, Vankov VN. Morphological aspects of secretion in the arterial smooth muscle cell, with special reference to the Golgi complex and microtubular cytoskeleton. Atherosclerosis 1986; 61(3): 175-192. [DOI: 10.1016/0021-9150(86)90013-2]

7. Lafont A, Libby P. The smooth muscle cell: sinner or saint in restenosis and the acute coronary syndromes? J Am Coll Cardiol 1998; 32(1): 283-285. [DOI: https://doi.org/10.1016/S0735-1097(98)00216-2]

8. Schwartz SM, Virmani R, Rosenfield ME. The good smooth muscle cells in atherosclerosis. Curr Atheroscler Rep 2000; 2(5): 422-429. [DOI: 10.1007/s11883-000-0081-5]

9. Dave T, Ezahl J, Vasnavahala H, Somani V. Plaque regression and plaque stabilisation in cardiovascular diseases. Indian J Endocrinol Metab 2013; 17(6): 983-989. [DOI: 10.4103/2230-8210.122604]

10. Daida H, Dohi T, Fukushima Y, Ohmura H, Miyauuki K. The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials. J Atheroscler Thromb 2019; 26(592-600. [DOI: 10.5551/jat.48603]

11. Guan S, Zhang Y, Wang B, Li W. Medical Therapy Induced Regression of Plaque in a Female Patient with ASCVD. Int Heart J 2019; 60(1): 175-177. [DOI: 10.1536/ihj.17-394]

12. Chaldakov GN. Colchicine, a microtubule-disassembling drug, in the therapy of cardiovascular diseases. Cell Biol Int 2018; 42(8): 1079-1084. [DOI: 10.1002/cbin.10988]

13. Chaldakov GN, Fiore M, Ghenev PI, Stankulov IS, Angelucci F, Pavlov PS, et al. Conceptual novelties in atherogenesis: smooth muscle cells, adventitia, and adipose tissue. Biomed Rev 2000; 11:63-67.

14. Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999; 41(2): 402-417. [DOI: 10.1016/s0008-6363(98)00279-x]

15. Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O. Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res 2014; 114(1): 214-226. [DOI: 10.1161/CIRCRESAHA.114.302355]

16. Takata K, Imaizumi S, Zhang B, Miura S-I, Saku K. Stabilization of high-risk plaques. Cardiovasc Diagn Ther 2016; 6(4): 304-321. [DOI: 10.21037/cdtt.2015.10.03]

17. Ylä-Herttuala S, Bentonz JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, et al. Stabilization of atherosclerotic plaques: an update. Eur Heart J 2013; 34(42): 3251-3258. [DOI: 10.1093/eurheartj/eh301]

18. Chen P-Y, Qin L, Li G, Tellides G, Simons M. Smooth muscle FGF/TGFβ cross talk regulates atherosclerosis progression. EMBO Mol Med 2016; 8(7): 712-728. [DOI: 10.15252/emmm.201506181]

19. Dong M, Zheng L, Chen WQ, Ji XP, Zhang M, Zhao YX, et al. Doxycycline stabilizes vulnerable plaque via inhibiting matrix metalloproteinases and attenuating inflammation in rabbits. PLoS one 2012; 7(6): e39695-e39695. [DOI: 10.1371/journal.pone.0039695]

20. Xiong W, Knispel RA, Dietz HC, Ramirez F, Baxter BT. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J Vasc Surg 2008; 47(1): 166-172; discussion 172. [DOI: 10.1016/j.vasc外科.2007.09.016]

21. Parker SJ, Stotland A, MacFarlane E, Wilson N, Orosco A, Venkatraman V, et al. Proteomics reveals Rictor as a noncanonical TGF-β signaling target during aneurysm progression in Marfan mice. Am J Physiol Heart Circ Physiol 2018; 315(5): H1112-H1126. [DOI: 10.1152/ajpheart.00089.2018]

22. Crosas-Molist E, Meirelles T, López-Luque J, Serra-Peina do C, Selva J, Caja L, et al. Vascular Smooth Muscle Cell Phenotypic Changes in Patients With Marfan Syndrome. Arterioscl Thromb Vasc Biol 2015; 35(4): 960-972. [DOI: doi:10.1161/ATVBAHA.114.304412]

23. Hibender S, Franken R, Roomen C, Braake AT, Made Ivd, Schermer EE, et al. Resveratrol Inhibits Aortic Root Dilatation in the Fbn1<sup>C1039G/+</sup> Marfan Mouse Model. Arterioscl Thromb Vasc Biol 2016; 36(8): 1618-1626. [DOI: doi:10.1161/ATVBAHA.116.307841]

24. Molloy KJ, Thompson MM, Jones JL, Schwalbe EC, Bell PR, Naylor AR, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 2004; 110(3): 337-343. [DOI: 10.1161/01.CIR.0000135588.65188.14]
25. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007; 17(8): 253-258. [DOI: 10.1016/j.tcm.2007.09.001]

26. Newby AC. Role of metalloproteinases in plaque rupture. Int J Gerontol 2007; 1(3): 103-111.

27. Ruddy JM, Ikonomidou JS, Jones JA. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability. J Vasc Res 2016; 53(1-2): 1-16. [DOI: 10.1159/000446703]

28. Johnson JL, Devel L, Czarny B, George SJ, Jackson CL, Rogakos V, et al. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 2011; 31(3): 528-535. [DOI: 10.1161/ATVBHA.110.219147]

29. Fredman G, Tabas I. Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am J Pathol 2017; 187(6): 1211-1221. [DOI: 10.1016/j.ajpath.2017.01.018]

30. Fredman G. Can Inflammation-Resolution Provide Clues to Treat Patients According to Their Plaque Phenotype? Front Pharmacol 2019; 10(205). [DOI: 10.3389/fphar.2019.00205]

31. Carracedo M, Artiach G, Arnardottir H, Bäck M. The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification. Semin Immunopathol 2019; 41(6): 757-766. [DOI: 10.1007/s00281-019-00767-y]

32. Viola JR, Lennitzer P, Jansen Y, Csaba G, Winter C, Neideck C, et al. Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogession in Mice. Circ Res 2016; 119(9): 1030-1038. [DOI: doi:10.1161/CIRCRESAHA.116.309492]

33. Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. J Intern Med 2009; 265(6): 663-679. [DOI: 10.1111/j.1365-2796.2009.02098.x]

34. Jharg J-F, Wang H-J, Hsu Y-H, Birder LA, Kuo H-C. Upregulation of neurotrophins and transforming growth factor-β expression in the bladder may lead to nerve hyperplasia and fibrosis in patients with severe ketamine-associated cystitis. Neurourol Urodyn 2019; 38(5): 2303-2310. [DOI: 10.1002/nau.24139]

35. Liu Z, Cao Y, Liu G, Yin S, Ma J, Liu J, et al. p75 neurotrophin receptor regulates NGF-induced myofibroblast differentiation and collagen synthesis through MRTF-A. Exp Cell Res 2019; 383(1): 111504. [DOI: https://doi.org/10.1016/j.yexcr.2019.111504]

36. Rocco ML, Soligo M, Manni L, Aloe L. Nerve Growth Factor: Early Studies and Recent Clinical Trials. Curr Neuropharmacol 2018; 16(10): 1455-1465. [DOI: 10.2174/1570159X16666180412092859]

37. Aloe L: Nerve growth factor, human skin ulcers and vascularization. Our experience. In: Progress in Brain Research. Volume 146: Elsevier, 2004; 515-522.

38. Aloe L, Tirassa P, Lambiase A. The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers. Pharmacol Res 2008; 57(4): 253-258. [DOI: https://doi.org/10.1016/j.phrs.2008.01.010]

39. Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, et al.: Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? In: Progress in Brain Research. Volume 146: Elsevier, 2004; 279-289.

40. Li H, Zhang L, Yin D, Zhang Y, Miao J. Targeting Phosphatidylcholine-Specific Phospholipase C for Atherogenesis Therapy. Trends Cardiovasc Med 2010; 20(5): 172-176. [DOI: https://doi.org/10.1016/j.tcm.2011.02.002]

41. Zhang L, Zhao J, Su L, Huang B, Wang L, Su H, et al. D609 inhibits progression of preexisting atheroma and promotes lesion stability in apolipoprotein e-/- mice: a role of phosphatidylcholine-specific phospholipase in atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30(3): 411-418. [DOI: 10.1161/ATVBHA.109.195768]

42. Zhao Y, Li K, Zhao B, Su L. Discovery of novel PC-PLC activity inhibitors. Chem Biol Drug Des 2019; 94(8). [DOI: 10.1111/cbddd.13606]

43. Meng A, Luberto C, Meier P, Bai A, Yang X, Hannun YA, et al. Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocyte leukemia cells. Exp Cell Res 2004; 292(2): 385-392. [DOI: 10.1016/j.yexcr.2003.10.001]

44. Li Y, Huang T, Lou B, Ye D, Qi X, Li X, et al. Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor. Eur J Med Chem 2019; 163(864-882. [DOI: https://doi.org/10.1016/j.ejmech.2018.12.028]

45. Kühnast S, van der Hoorn JWA, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res 2014; 55(10): 2103-2112. [DOI: 10.1194/jlr.M051326]

46. Hafiane A. Vulnerable Plaque, Characteristics, Detection, and Potential Therapies. J Cardiovasc Dev Dis 2019; 6(3): 26. [DOI: 10.3390/jcdd6030026]

47. Tang J, Lobatto ME, Hassing L, van der Staay S, van Rijs SM, Calcagno C, et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci Adv 2015; 1(3). [DOI: 10.1126/sciadv.1400223]